Why the study?
Does diabetes treatment type affect the risk of ventricular arrhythmias in early survivors of acute myocardial infarction compared to patients without diabetes?
Does diabetes treatment type affect the risk of ventricular arrhythmias in early survivors of acute myocardial infarction compared to patients without diabetes?
In early survivors of acute myocardial infarction, patients with diabetes treated with insulin or second-generation sulphonylureas have a lower risk of ventricular arrhythmias compared to patients without diabetes.
Answers are grounded in this paper and cite their sources.
Should not yet change post-MI diabetes management; hypothesis-generating and requires prospective confirmation.
AIMS: To evaluate the effect of diabetes mellitus and its treatment on the risk of arrhythmias among early survivors of acute myocardial infarction. RESEARCH DESIGN AND METHOD: The Onset Study was conducted in 64 US medical centres. Between August 1989 and September 1996, 3882 patients were interviewed after having an acute myocardial infarction. We used logistic regression models to examine the association of diabetes and its treatment with the risk of ventricular arrhythmia after adjustment for age, gender, hypertension, thrombolytic therapy, smoking, obesity, cardiac medicines and congestive heart failure. RESULTS: During the index hospitalization, patients with diabetes (n=814) were less likely to develop ventricular arrhythmias than patients without diabetes (6.8 vs. 13.3%, P<0.001). The risk of ventricular arrhythmia in patients treated with first generation sulphonylureas or diet alone was similar to patients without diabetes (OR=0.91; 95% CI, 0.39-2.15, and 0.76; 95% CI, 0.46-1.26, respectively). However, compared with patients without diabetes, the adjusted odds ratio (OR) for ventricular arrhythmias was lower among patients treated with insulin or patients treated with second generation sulphonylureas (OR=0.54, 95% CI 0.32-0.92; OR=0.45, 95% CI 0.27-0.75, respectively). CONCLUSIONS: Compared with patients without diabetes, the risk of ventricular arrhythmias complicating acute myocardial infarction is lower in patients with diabetes treated with second generation sulphonylureas or insulin, but not in those treated with first generation sulphonylureas or diet alone. This suggests that differences in the mechanism of action of different sulphonylureas may result in clinically relevant differences in arrhythmic risk.
No takes yet. Share an insight, caveat, or question.
Rana et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: